Key result
Low-dose oral propranolol (20 mg) significantly improved symptom burden compared with placebo (median change -4.5 vs 0 arbitrary units; P=0.044) in POTS, whereas 80 mg may worsen symptoms.
Why the study?
Does oral propranolol attenuate tachycardia and improve symptom burden in patients with Postural Tachycardia Syndrome (POTS)?
RCT (n=72)
Crossover
Does oral propranolol attenuate tachycardia and improve symptom burden in patients with Postural Tachycardia Syndrome (POTS)?
Absolute Event Rate: -4.5% vs 0%
p-value: p=0.044
Low-dose oral propranolol (20 mg) effectively attenuates standing tachycardia and improves symptoms in POTS, whereas higher doses (80 mg) offer no additional symptomatic benefit and may worsen symptoms.
No takes yet. Share an insight, caveat, or question.
Low-dose propranolol improves POTS symptoms; supports initial 20 mg dosing and challenges higher-dose regimens in practice and trials.
Raj et al. (2009) conducted an RCT in Postural Tachycardia Syndrome (POTS) (n=72). Propranolol vs. Placebo was evaluated on Symptom burden improvement from baseline to 2 hours (arbitrary units) (p=0.044). Low-dose oral propranolol (20 mg) significantly improved symptom burden compared with placebo (median change -4.5 vs 0 arbitrary units; P=0.044) in POTS, whereas 80 mg may worsen symptoms.